A Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab

PurposeThis is an observational study of a drug called Xolair (omalizumab).The main purpose of the study is to provide a complete assessment of response to omalizumab. Information gathered from this study will assist health care providers in selecting appropriate patients who may benefit from treatment, and also guide your doctor with measuring responses to omalizumab treatment more accurately. Your total length of time in the study will be about 48 weeks.

EligibilityAnyone 12 years and older have made a decision with their doctor to initiate treatment with omalizumab for their asthma may be eligible to participate in the study.


Genentech, Inc.


Principal Investigator: Tara F. Carr, MD

Contact Information:

Osmara Y. Molina de Rodriguez, MS
Cell: (520) 891-6767 or Office: (520) 626-3910
Study Status: